Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antioxidant inflammation modulators - Reata Pharmaceuticals

Drug Profile

Research programme: antioxidant inflammation modulators - Reata Pharmaceuticals

Alternative Names: AIMs - Reata; CDDO-Im; Nrf2 activators - Reata Pharmaceuticals; RTA 403; RTA 404; RTA dh404; RTA-411; Synthetic triterpenoids - Reata; TBEs - Reata/Abbott; Tricyclic bis-enones - Reata

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer Reata Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Anti-inflammatories; Antineoplastics; Ketones; Neuroprotectants; Triterpenes
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Chronic obstructive pulmonary disease; Neurological disorders

Most Recent Events

  • 10 Oct 2019 Preclinical development is ongoing for Autoimmune disorders, Cancer, Neurological disorders, Chronic obstructive pulmonary disease in USA
  • 10 Oct 2019 Reata Pharmaceuticals reacquires rights from AbbVie to develop and commercialise Nrf2 activators worldwide
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top